Active clinical trials for Neurology:

TITLE DESCRIPTION
A multicenter, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuropyelitis optica (NMO) To evaluate the effectiveness and safety of under the skin injection of SA237 as monotherapy in patients with NMO.
More information
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Episodic migraine is a diagnosis applied to patients with migraine who experience 1-14 headache days per month. The study drug in this trial, DFN-15 (celecoxib oral solution), is an NSAID. Migraine treatment with NSAIDs can produce analgesia similar to that from opioid treatment, while sparing patients from opioid-associated side effects (i.e. sedation, nausea, and/or vomiting). The objective of this trial is to demonstrate the tolerability, safety, and efficacy of DFN-15 for the acute relief of migraine. This study will assess the proportion of patients who are free from pain and/or their most bothersome migraine symptom after treatment with the study drug.
More information
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention Episodic migraine is a diagnosis applied to patients with migraine who experience 1-14 headache days per month. CGRP (calcitonin gene-related peptide) is a neuropeptide that has been implicated in the pathophysiology of migraine. The study drug in this trial, AGN-241689, is a CGRP receptor antagonist being developed for migraine prevention. The objective of this study is to assess the safety, tolerability and efficacy of AGN-241689 compared with placebo in the prevention of episodic migraine.
More information
Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE) To develop a protocl to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.
More information